ConductScience.org, home

Paper38374366

The changing landscape of thyroid eye disease: current clinical advances and future outlook.

Moledina M and 2 others. Eye (Lond), 2024. Cited by 52 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. The changing landscape of thyroid eye disease: current clinical advances and future outlook. Papers, record 38374366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38374366

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The changing landscape of thyroid eye disease: current clinical advances and future outlook.
PubMed
Journal
Eye (Lond)
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
52
iCite
Relative citation ratio, by iCite
13.05, provisional
iCite
Revised in PubMed
2024-06-27
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Moledina MMalikhttps://orcid.org/0000-0003-3554-7797
2Damato EMErika M
3Lee VVickiehttps://orcid.org/0000-0002-2963-5742

Source PubMed

Download CSV of authors

Topics3

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Graves OphthalmopathyMajor topic
Humans
Antibodies, Monoclonal, Humanized

References144

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135227694Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.Am J Ophthalmol2022https://conductscience.org/library/papers/35227694PubMed
231354709The Neonatal Fc Receptor (FcRn): A Misnomer?Front Immunol2019https://conductscience.org/library/papers/31354709PubMed
310720061Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy.J Clin Endocrinol Metab2000https://conductscience.org/library/papers/10720061PubMed
415998777Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy.J Clin Endocrinol Metab2005https://conductscience.org/library/papers/15998777PubMed
529396246Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.Lancet Diabetes Endocrinol2018https://conductscience.org/library/papers/29396246PubMed
635604323Current concepts regarding Graves' orbitopathy.J Intern Med2022https://conductscience.org/library/papers/35604323PubMed
732107168Graves' disease: Epidemiology, genetic and environmental risk factors and viruses.Best Pract Res Clin Endocrinol Metab2020https://conductscience.org/library/papers/32107168PubMed
833511081Proposal for Standardization of Primary and Secondary Outcomes in Patients with Active, Moderate-to-Severe Graves' Orbitopathy.Eur Thyroid J2020https://conductscience.org/library/papers/33511081PubMed
918786258Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.Arthritis Res Ther2008https://conductscience.org/library/papers/18786258PubMed
1036683389Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study.J Clin Endocrinol Metab2023https://conductscience.org/library/papers/36683389PubMed
1135709102Rituximab for thyroid-associated ophthalmopathy.Cochrane Database Syst Rev2022https://conductscience.org/library/papers/35709102PubMed
1212794168Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway.J Immunol2003https://conductscience.org/library/papers/12794168PubMed
1324916606Methotrexate for treating rheumatoid arthritis.Cochrane Database Syst Rev2014https://conductscience.org/library/papers/24916606PubMed
1419221109Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy.Br J Ophthalmol2009https://conductscience.org/library/papers/19221109PubMed
159530102Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production.Am J Physiol1998https://conductscience.org/library/papers/9530102PubMed
1627760790MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials.Eur J Endocrinol2017https://conductscience.org/library/papers/27760790PubMed
172519530Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy.N Engl J Med1989https://conductscience.org/library/papers/2519530PubMed
1833783712Intravenous rituximab therapy for active Graves' ophthalmopathy: a meta-analysis.Hormones (Athens)2021https://conductscience.org/library/papers/33783712PubMed
1924783001Oxidative stress in graves' disease.Eur Thyroid J2012https://conductscience.org/library/papers/24783001PubMed
2021591944Selenium and the course of mild Graves' orbitopathy.N Engl J Med2011https://conductscience.org/library/papers/21591944PubMed

See all 144 referencesDownload CSV of references

Cited by35

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 52 citations.

PMIDTitleJournalYearIn PapersSource
42941257Systemic Inflammatory Markers, Thyroid Autoimmunity, and Neuroretinal Structure in Graves' Disease: A Comparative OCT Study According to Ophthalmopathy Status.Metabolites2026https://conductscience.org/library/papers/42941257PubMed
42787010Association between serum immunoglobulin G4 levels and Graves' ophthalmopathy: a meta-analysis.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42787010PubMed
42766069Quantitative evaluation of synthetic MRI for assessing disease activity in thyroid eye disease.Eur Radiol Exp2026https://conductscience.org/library/papers/42766069PubMed
42741468How to manage thyroid eye disease: recent advances - a narrative review.Drugs Context2026https://conductscience.org/library/papers/42741468PubMed
42671097Efficacy and safety of secondary infero-medial orbital wall decompression after orbital fat decompression in Graves' orbitopathy: A 12-year experience.Indian J Ophthalmol2026https://conductscience.org/library/papers/42671097PubMed
42518709Patients with Thyroid Eye Disease Initiating Teprotumumab: A Real-World Cohort Study Using the Linked IRIS-Komodo Database.Clin Ophthalmol2026https://conductscience.org/library/papers/42518709PubMed
42455407Audiometric changes during teprotumumab therapy for thyroid eye disease: a prospective pilot study.Endocrine2026https://conductscience.org/library/papers/42455407PubMed
41697457The role of monoclonal antibodies against IL-6 or IL-6R in the treatment of thyroid eye disease.Rev Endocr Metab Disord2026https://conductscience.org/library/papers/41697457PubMed
41675362Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization.Laryngoscope Investig Otolaryngol2026https://conductscience.org/library/papers/41675362PubMed
41533941Transcriptomic Profiling of Orbital Fat Tissue and Ocular Surface Wash in Active Thyroid Eye Disease Requiring Urgent Orbital Decompression.Invest Ophthalmol Vis Sci2025https://conductscience.org/library/papers/41533941PubMed
41509944Clinical characteristics of Graves' disease following COVID-19 infection or vaccination: a multicenter case-control study.Turk J Med Sci2025https://conductscience.org/library/papers/41509944PubMed
41495351Enhancing ocular sign detection: AI-based strategic segmentation for improved accuracy and privacy protection.NPJ Digit Med2026https://conductscience.org/library/papers/41495351PubMed
41462485Modulation of gut microbiota in Graves' orbitopathy: Prevotella dominance and atorvastatin's impact.Microbiome2025https://conductscience.org/library/papers/41462485PubMed
41322343Evaluation of clinical and ocular surface changes in thyroid eye disease: impact of treatment and risk factors.Ther Adv Ophthalmol2025https://conductscience.org/library/papers/41322343PubMed
41316028Clinical value of dual-energy CT parameters combined with morphological features in predicting graves' ophthalmopathy.BMC Med Imaging2025https://conductscience.org/library/papers/41316028PubMed
41246121Advancing the Therapeutic Frontier in Thyroid Eye Disease.touchREV Endocrinol2025https://conductscience.org/library/papers/41246121PubMed
41180578The role of mycophenolate mofetil in the therapy of thyroid eye disease.Ther Adv Endocrinol Metab2025https://conductscience.org/library/papers/41180578PubMed
40834360Exploring thyroid eye disease in Brazil: insights from a single-center study.Arch Endocrinol Metab2025https://conductscience.org/library/papers/40834360PubMed
40807149Redefining Treatment Paradigms in Thyroid Eye Disease: Current and Future Therapeutic Strategies.J Clin Med2025https://conductscience.org/library/papers/40807149PubMed
40787463Emerging therapeutic approaches in graves' ophthalmopathy: an update on pharmacological interventions.Front Immunol2025https://conductscience.org/library/papers/40787463PubMed

See all 35 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38374366

GET https://conductscience.org/api/papers/v1/38374366/references?page=2